Myelodysplastic Syndromes Clinical Trials in Minneapolis, Minnesota

5 studies are recruiting for myelodysplastic syndromes in Minneapolis, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

   This is a Phase I dose finding study of GTB-3650 (anti-CD16/IL-15/anti-CD33) Tri-Specific Killer Engager (TriKE®) for the treatment of select CD33-expressing refractory/relapsed myeloid malignancies in adults ≥ 18 years of age who are not a candidate for potentially curative therapy, including hema…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Masonic Cancer Center, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT06594445 on ClinicalTrials.gov

2. Allo HSCT Using RIC and PTCy for Hematological Diseases

   This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamid…

   Stage

   Phase 2

   Ages

   Up to 75

   Site

   Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT05805605 on ClinicalTrials.gov

3. MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

   This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophylaxis.

   Stage

   Phase 2

   Ages

   2 to 75

   Site

   Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT07493538 on ClinicalTrials.gov

4. Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

   This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune…

   Stage

   Phase 2

   Ages

   Up to 65

   Site

   Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT03579875 on ClinicalTrials.gov

5. Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

   The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will b…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Minnesota, Minneapolis, Minnesota

   Locations

   5 in total

   Run by

   Tr1X, Inc.

   See if you can join NCT06462365 on ClinicalTrials.gov